Genmab — Maj 2019
-
I anledning af debuten fik Andrew fire spørgsmål på forhånd fra mig i morges som forsmag på, hvad der der ventede ham ved vores Q&A. Det gjorde jeg af hensyn til afviklingen, hvor vi skal have besvaret så mange spørgsmål som muligt på 45 minutter.
-
Det samme gør jeg med Zealand Pharmas nye CEO Emmanuel Dulac, når vi har Q&A med ham d. 29. maj.
-
God morgen
-
God morgen.
-
-
@NoHope, 2 sjæle en tanke
-
Poseida Therapeutics Reseives US FDA Orphan Drug designation for P-BCMA 101 for the treatment of MM https://m.firstwordpharma.com/poseida-therapeutics-receives-us-fda-orphan-drug-designation-p-bcma-101-treatment-multiple-myeloma
-
-
-
Synes ikke der er meget RTOR over den MAIA ansøgning. Jeg ved ikke om jeg forstår den her tegning https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program men kan det passe at Janssen completed sBLA submission den 12. marts? https://johnsonandjohnson.gcs-web.com/static-files/5cec96a8-449f-4608-8890-a83c0b00d0b9 Herfra går der ifølge FDA ca. 4 uger? nu er der så gået 8 uger.
-
Winkel fra CC om RTOR og Maia: It's up to the gods at the FDA right now, but I think the process is going well, and there is no reason to be concerned at all. It's an experimental program. It's a pilot program. So the time lines are not fixed, but we expect it very, very shortly.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind